Program: Oral and Poster Abstracts
Session: 636. Myelodysplastic Syndromes – Basic and Translational Studies: Poster I
Aims: To explore the expression of a profile of miRNAs in patients with MDS and NK, assessing the role of them in the risk stratification.
Patients and methods: Based on previous works of our group (Andres-Coduras, et al, ELN 2012; Andres-Codura, et al, SEHH 2013), a miRNAs profile, composed by 14 miRNAs over more than 7,000 miRNAs, was identified, on 40 patients with MDS compared to controls. This profile was analyzed in 243 plasma samples from patients with MDS at diagnosis from the INBIOMED group, previously ethic committee and board approval were required and patients signed an inform consent according the Helsinki declaration revised in 2013. Here, we are presenting a subanalysis including only patients with NK. The miRNA profile included: hsa-miR-26a, hsa-miR-451, hsa-miR-99b, hsa-miR-24, hsa-miR-625, hsa-miR-15b, hsa-miR-19b, hsa-let-7e, hsa-miR-16, hsa-miR-140-3p, hsa-miR361-3p, hsa-miR-378 and hsa-miR-942.
Results: From 154 plasma of NK-MDS patients. All of them classified as very good, good and intermediate risk category by IPSS-R or low and intermedium-1 by IPSS, a total of 143 have associated follow-up information at 2 years of diagnosis. Thirty-seven patients evolved to AML or died in this time. 4 miRNAs differentially expressed (miRNA140-3p, miRNA-15b, miRNA-99b-5p and miRNA-361-3p) showed advantage to identified patients with MDS. Based in IPSS-R, patients were classified as good prognosis group (no candidates to therapy) and high risk group (candidates to therapy). An increase in both the expression of miR-140-3p and miR-99b-5p was able to identified patients with MDS and NK with good prognosis independently of IPSS-R risk category, improving the identification of patients with good outcomes (ROC curve for IPSS-R: 0,669 and for miRNAs model: 0,785), contrary, the underexpression of both miRNAs was a predictor of worse outcomes.
Comments: Here we describe a non-previously described signature of miRNAs that can improve the classification of MDS patients without cytogenetic alterations, especially for patients with good or intermediate risk group. miRNAs could be a good biomarkers during follow-up considering their variations and easy assessment.
Disclosures: Ramos: Amgen: Consultancy , Honoraria ; GlaxoSmithKline: Honoraria ; Janssen-Cilag: Honoraria , Membership on an entity’s Board of Directors or advisory committees ; Novartis: Consultancy , Honoraria ; Celgene Corporation: Consultancy , Honoraria , Membership on an entity’s Board of Directors or advisory committees , Research Funding .
See more of: Myelodysplastic Syndromes – Basic and Translational Studies
See more of: Oral and Poster Abstracts
*signifies non-member of ASH